OTCMKTS:LTUS

Lotus Pharmaceuticals Stock Forecast, Price & News

$0.04
-0.01 (-20.00 %)
(As of 04/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.04
Now: $0.04
$0.05
50-Day Range
$0.04
MA: $0.10
$0.20
52-Week Range
$0.01
Now: $0.04
$0.22
Volume98,410 shs
Average Volume166,825 shs
Market Capitalization$117.78 million
P/E RatioN/A
Dividend YieldN/A
Beta1.29
Lotus Pharmaceuticals, Inc. develops, manufactures, and sells pharmaceuticals in the People's Republic of China. The company markets valsartan capsules under the Maixin name to treat hypertension; eye drops under the Muxin name to treat glaucoma; and Octreotide Acetate Injection solution under the Yipubishan name for treating gastric ulcers. It also offers Junxin branded Levofloxacin, an anti-bacterial drug for the treatment of mild, moderate, and severe infections caused by susceptible trains of the designated microorganisms in the conditions such as acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, complicated and uncomplicated skin and skin structure infections, complicated and uncomplicated urinary tract infections, and acute pyelonephritis; and Nicergoline for Injection, an a-receptor blockage nerve system blood-brain medicine. The company's products under development include R-Bambuterol-Class 1 for the treatment of asthma; Gliclazide-controlled release tablets for the treatment of diabetes; Isosorbide Mononitrate-tablets for the treatment of cardiovascular-coronary artery; Verapamil Hydrochloride tablets for the treatment of cardiovascular-irregular angina; and Lovastatin tablets, Valsartan-controlled release tablets, and Hawthorn Flavonoids tablets for the treatment of cardiovascular-hyperlipemia. It also involves in retailing Western and traditional Chinese medications, and medical treatment equipment through 10 retail pharmacy locations; performing research and development, and lab testing projects for third parties; and leasing retail space to licensed physicians, and merchants in the retail pharmacies. The company sells its products through a nationwide sales network to hospitals, clinics, and drugs stores. Lotus Pharmaceuticals, Inc. is based in Beijing, the People's Republic of China.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:LTUS
CUSIPN/A
CIKN/A
Phone86 10 6389 9868
Employees233
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Outstanding Shares2,944,520,000
Market Cap$117.78 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1993rd out of 2,018 stocks

Pharmaceutical Preparations Industry

766th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.04
-0.01 (-20.00 %)
(As of 04/19/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LTUS News and Ratings via Email

Sign-up to receive the latest news and ratings for LTUS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Lotus Pharmaceuticals (OTCMKTS:LTUS) Frequently Asked Questions

What stocks does MarketBeat like better than Lotus Pharmaceuticals?

Wall Street analysts have given Lotus Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Lotus Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Lotus Pharmaceuticals?

Lotus Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 23,900 shares, an increase of 106.0% from the March 15th total of 11,600 shares. Based on an average trading volume of 285,400 shares, the days-to-cover ratio is presently 0.1 days.
View Lotus Pharmaceuticals' Short Interest
.

Who are Lotus Pharmaceuticals' key executives?

Lotus Pharmaceuticals' management team includes the following people:
  • Dr. Zhong Yi Liu, Founder, Chairman, Chief Exec. Officer and Pres (Age 60, Pay $180k)
  • Ms. Yan Zeng, Chief Financial Officer and Principal Accounting Officer (Age 52)
  • Dr. Xing Shen, VP of Corp. Devel. (Age 50)

Who are some of Lotus Pharmaceuticals' key competitors?

What is Lotus Pharmaceuticals' stock symbol?

Lotus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "LTUS."

How do I buy shares of Lotus Pharmaceuticals?

Shares of LTUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lotus Pharmaceuticals' stock price today?

One share of LTUS stock can currently be purchased for approximately $0.04.

How much money does Lotus Pharmaceuticals make?

Lotus Pharmaceuticals has a market capitalization of $117.78 million.

How many employees does Lotus Pharmaceuticals have?

Lotus Pharmaceuticals employs 233 workers across the globe.

What is Lotus Pharmaceuticals' official website?

The official website for Lotus Pharmaceuticals is www.lotuspharma.com.

Where are Lotus Pharmaceuticals' headquarters?

Lotus Pharmaceuticals is headquartered at 16 CHENG ZHUANG ROAD FENG TAI DISTRICT, BEIJING F4, 100071.

How can I contact Lotus Pharmaceuticals?

Lotus Pharmaceuticals' mailing address is 16 CHENG ZHUANG ROAD FENG TAI DISTRICT, BEIJING F4, 100071. The company can be reached via phone at 86 10 6389 9868.


This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.